ADC Therapeutics (ADCT)
(Delayed Data from NYSE)
$2.94 USD
+0.01 (0.34%)
Updated Sep 11, 2024 04:00 PM ET
After-Market: $2.95 +0.01 (0.34%) 4:44 PM ET
3-Hold of 5 3
F Value C Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.94 USD
+0.01 (0.34%)
Updated Sep 11, 2024 04:00 PM ET
After-Market: $2.95 +0.01 (0.34%) 4:44 PM ET
3-Hold of 5 3
F Value C Growth C Momentum D VGM
Zacks News
ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
ADC Therapeutics (ADCT) delivered earnings and revenue surprises of 13.64% and 8.63%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Vertex Pharmaceuticals (VRTX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Vertex (VRTX) delivered earnings and revenue surprises of -11.57% and 0.08%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
ADC Therapeutics (ADCT) delivered earnings and revenue surprises of 0% and 0.75%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of -119.15% and 1.25%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Adobe (ADBE) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Adobe's (ADBE) first-quarter fiscal 2024 results are expected to reflect gains from the solid momentum across the Digital Media and Digital Experience segments.
SentinelOne (S) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
SentinelOne's (S) fourth-quarter fiscal 2024 performance is expected to have benefited from its robust growth in the Singularity platform.
Zymeworks Inc. (ZYME) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of 48.72% and 7.59%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Cytek Biosciences, Inc. (CTKB) Q4 Earnings Expected to Decline
by Zacks Equity Research
Cytek Biosciences, Inc. (CTKB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: ADC Therapeutics SA (ADCT) Q4 Earnings Expected to Decline
by Zacks Equity Research
ADC Therapeutics SA (ADCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biogen Inc. (BIIB) Lags Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Biogen Inc. (BIIB) delivered earnings and revenue surprises of -6.65% and 2.88%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
ADC Therapeutics (ADCT) Rises 43% in a Month: Here's Why
by Zacks Equity Research
ADC Therapeutics (ADCT) surges after it provides business updates that highlight the company's progress with its pipeline. Multiple data readouts are expected throughout this year.
Is ADC Therapeutics (ADCT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how ADC Therapeutics SA (ADCT) and CytomX Therapeutics (CTMX) have performed compared to their sector so far this year.
ADC Therapeutics SA (ADCT) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 4.92% and 0.53%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Puma Biotech (PBYI) Tops Q3 Earnings Estimates
by Zacks Equity Research
Puma Biotech (PBYI) delivered earnings and revenue surprises of 13.33% and 3.16%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Ligand Pharmaceuticals (LGND) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Ligand (LGND) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ADC Therapeutics SA (ADCT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
ADC Therapeutics SA (ADCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Atreca (BCEL) Suspends Lead Drug Evaluation, Stock Falls 37%
by Zacks Equity Research
Atreca (BCEL) suspends the development of only pipeline candidate, ATRC-101, in clinical evaluation, as part of its business restructuring efforts and cuts headcount by 40%. The stock falls 37%.
Catalyst (CPRX) Q2 Earnings & Sales Top, 2023 Outlook Raised
by Zacks Equity Research
Catalyst (CPRX) reports better-than-expected second-quarter 2023 results. Management raises full-year 2023 guidance.
Novo Nordisk (NVO) Q2 Earnings and Sales Miss, 2023 View Up
by Zacks Equity Research
Novo Nordisk (NVO) reports weaker-than-expected second-quarter 2023 results, missing both earnings and sales estimates. Management, however, raises 2023 guidance.
Deciphera (DCPH) Q2 Earnings Beat, Qinlock Drives Revenues
by Zacks Equity Research
Deciphera (DCPH) reports narrower-than-expected loss for the second quarter of 2023. Qinlock drives year-over-year sales.
Horizon (HZNP) Q2 Earnings Top, Krystexxa & Uplizna Boost Sales
by Zacks Equity Research
Horizon (HZNP) reports better-than-expected second-quarter results, beating both earnings and sales estimates, with the top-line key contributors being Krystexxa and Uplizna.
Emergent (EBS) Q2 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Emergent (EBS) reports wider-than-expected second-quarter loss. The company lowered its 2023 guidance for some products and services.
Amicus (FOLD) Misses on Q2 Earnings, Raises Revenue Guidance
by Zacks Equity Research
Amicus (FOLD) incurs wider-than-expected loss in the second quarter. Fabry disease drug Galafold reports encouraging revenues and the company raises its 2023 guidance for the same.
Ironwood's (IRWD) Reports Q2 Loss, Linzess Volume Rises
by Zacks Equity Research
Ironwood (IRWD) reports loss for second-quarter 2023. The top line increases year over year, driven by growth in Linzess collaboration revenues.
Zoetis' (ZTS) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Zoetis (ZTS) reports better-than-expected second-quarter 2023 results, beating both earnings and revenue estimates, primarily driven by the sales of its key dermatology products.